Randomized, blinded, placebo-controlled trial of tissue factor pathway inhibitor in porcine septic shock

Shock

Volumn 10, Issue 4, 1998, Pages 258-264

  Goldfarb, Roy D ^a   Glock, Dana ^a   Johnson, Kirk ^b   Creasey, Abla A ^b   Carr, Christina ^c   McCarthy, Robert J ^a   Matushek, Marian ^a   Akhter, Imran ^a   Trenholme, Gordon ^a   Parrillo, Joseph E ^a  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 8; LIPOPROTEIN; LIPOPROTEIN-ASSOCIATED COAGULATION INHIBITOR; PLACEBO; TISSUE FACTOR PATHWAY INHIBITOR; TUMOR NECROSIS FACTOR ALPHA;

ANIMAL; ARTICLE; BLOOD; BLOOD PRESSURE; DRUG EFFECT; DRUG SCREENING; HEART; HEART RATE; MORTALITY; RANDOMIZATION; SEPTIC SHOCK; SINGLE BLIND PROCEDURE; SURVIVAL RATE; SWINE; TIME;

ANIMALS; BLOOD PRESSURE; DRUG EVALUATION, PRECLINICAL; HEART; HEART RATE; INTERLEUKIN-8; LIPOPROTEINS; PLACEBOS; RANDOM ALLOCATION; SHOCK, SEPTIC; SINGLE-BLIND METHOD; SURVIVAL RATE; SWINE; TIME FACTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0032184952     PISSN: 10732322     EISSN: None     Source Type: Journal    
DOI: 10.1097/00024382-199810000-00005     Document Type: Article

References (37)

1. Marder VI: Consumptive thrombohemorrhagic disorders. In Williams WJ, Beutier E, Erslev AJ, Lichtman MA (eds): Hematology. New York: McGraw-Hill Book Company, pp 1433-1461, 1983.
2. Rivers RA, Hathaway WE, Weston WL: The endotoxin induced coagulant activity of human monocytes. Br J Haematol 30:311-316, 1975.
3. Colucci M, Balconi G, Lorenzet R, et al: Cultured human endothelial cells generate tissue factor in response to endotoxin. J Clin Invest 71:1893-1896, 1983.
4. Lyberg T, Gaidal TA, Evansen SA, Pryctz H: Cellular cooperation in endothelial cell thromboplastin synthesis. Br J Haematol 53:85-95, 1983.
5. Nawroth PP, Handley DA, Esmon TA, Stern DM: Interleukin-1 induces endothelial cell procoagulant while suppressing cell-surface anticoagulant activity. Proc Natl Acad Sci USA 83:3460-3464, 1986.
6. Bevilacqua MP, Pober JS, Majeau GR, Fiers W, Cotran RS, Gimbrone MA: Recombinant tumor necrosis factor induces procoagulant activity in cultured human vascular endothelium: Characterization comparison with the actions of interleukin-1. Proc Natl Acad Sci USA 83:4533-4537, 1986.
7. Girard TJ, Warren LA, Novotny WF, et al: Functional significance of the Kunitz-type inhibitory domains of lipoprotein-coated coagulation inhibitor. Nature 338:518-520, 1989.
8. Sandset PM, Warn-Cramer BJ, Vijava L, Rao M, Maki SL, Rapaport M: Depiction of extrinsic pathway inhibitor (EPI) sensitizes rabbits to disseminated intravascular coagulation induced with tissue factor: Evidence supporting a physiologic role for EPI as a natural anticoagulant. Proc Natl Acad Sci USA 88:708-712, 1991.
9. Ameri A, Kuppuswam MN, Basu S, Bajaj SP: Expression of tissue factor pathway inhibitor by cultured endothelial cells in response to inflammatory mediators. Blood 79:3219-3226, 1992.
10. Wun T-C, Kretzmer KK, Palmier MD, et al: Comparison of recombinant tissue factor pathway inhibitors expressed in human SK hepatoma, mouse C127, baby hamster kidney, Chinese hamster ovary cells. Thromb Haemostasis 68:54-59, 1992.
11. Creasey AA, Chang ACK, Feigen L, Wun T-C, Taylor FB Jr, Hinshaw LB: Tissue factor pathway inhibitor reduces mortality from E. coli septic shock. J Clin Invest 91:2850-2860, 1993.
12. Carr C, Bild GS, Chang ACK, Peer GT, et al: Recombinant E. coli-derived tissue factor pathway inhibitor reduces coagulopathic and lethal effects in the baboon gram-negative model of septic shock. Circ Shock 44:126-137, 1995.
13. Goldfarb RD, Glock D, Kumar A, et al: A porcine model of peritonitis simulates human septic shock. Shock 6:442-451, 1996.
14. Natanson C, Fink MP, Ballantyne HK, MacVittie TJ, Conklin JC, Parrillo JE: Gram negative bacteremia produces both severe systolic and diastolic cardiac dysfunction in a canine model that simulates human septic shock. J Clin Invest 78:259-270, 1986.
15. Parrillo JE, Parker MM, Natanson C, et al: Septic shock in humans. Ann Intern Med 113:227-242, 1990.
16. Gustafson ME, Junger KD, Wun T-C, et al: Renaturation and purification of human tissue factor pathway inhibitor expressed in recombinant E. coli. Prot Expression Purification 5:233-241, 1994.
17. Johnson K, Arden L, Choi Y, DeGroot E, Creasey AA: The proinflammatory cytokine response to coagulation and endotoxin in whole blood. Blood 87:5051-5060, 1996.
18. Haskel EJ, Torr SR, Day KC, et al: Prevention of arterial reocclusion after thrombolysis with recombinant lipoprotein-associated coagulation inhibitor. Circulation 84:821-827, 1991.
19. Abendschein DR, Meng YY, Torr-Brown S, Sobel BE: Maintenance of coronary patency after fibrinolysis with tissue factor pathway inhibitor. Circulation 92:944-949, 1995.
20. Parrillo JE: Pathogenic mechanisms of septic shock. N Engl J Med 328:1471-1417, 1993.
21. Walvatne CS, Johnson AS, Wojcik LJ, Cerra FB: Cardiovascular response to acute and chronic endotoxemia in an awake, volume-resuscitated, canine model. Shock 3:299-307, 1995.
22. Parker MM, Shelhammer JL, Green MV, et al: Profound but reversible myocardial depression in patients with septic shock. Ann Intern Med 100:483, 1984.
23. Van der Poll T, Lowery SF: Tumor necrosis factor in sepsis: Mediator of multiple organ failure or essential part of host defense. Shock 3:1-12, 1995.
24. Mackman N: Regulation of tissue factor gene. Thromb Haemost 78:747-754, 1997.
25. Hara S, Asada Y, Hatakeyama K, et al: Expression of tissue factor and tissue factor pathway inhibitor in rat lungs with LPS-induced DIC. Lab Invest 77:581-589, 1997.
26. Semeraro N, Colucci M: Tissue factor in health and disease. Thromb Haemost 78:759-764, 1997.
27. Bajaj MS, Bajaj SP: Tissue factor pathway inhibitor: Potential therapeutic applications. Thromb Haemost 78:471-477, 1997.
28. Taylor FB Jr, Chang A, et al: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody. Circ Shock 33:127-134, 1991.
29. Moore KL, Andreoli SP, Esmon NL, Esmon CT, Bang NU: Endotoxin enhances tissue factor and suppresses thrombomodulin expression in human vascular endothelium in vitro. J Clin Invest 79:124-130, 1987.
30. Ameri A, Kuppuswamy MN, Basu S, Bajaj SP: Expression of TFPI by cultured endothelial cells in response to inflammatory mediators. Blood 79:3219-3226, 1992.
31. Taylor FB Jr, Chang A, Ruf W, et al: Lethal E. coli septic shock is prevented by blocking tissue factor with monoclonal antibody Circ Shock 33:127-133, 1991.
32. Levi M, ten Cate H, Bauer KA, et al: Inhibition of endotoxin-induced activation of coagulation and fibrinolysis by pentoxifylline or by a monoclonal anti-tissue factor antibody in chimpanzees. J Clin Invest 93:114-120, 1994.
33. Camerota AJ, Creasey AA, Patla B, Larkin VA, Fink MA: Delayed treatment with recombinant human tissue factor pathway inhibitor improves survival in rabbits with gram-negative peritonitis. J Infect Dis 177:668-676, 1998.
34. Goldfarb RD, Bennett CF, Glock D, Gerogakopoulus N, Akhter I, Parrillo JE. In vitro and in vivo inhibition of endotoxin-induced porcine E-selectin expression by antisense oligonucleotides. Exp Biol 1997.
35. Ten Cate JW, van der Poll T, Levi M, ten Cate H, van Deventer SJ: Cytokines: Triggers of clinical thrombotic disease. Thromb Haemost 78: 415-419; 1997.
36. Johnson K, Hung D: Novel anticoagulants based on inhibition of the factor VIIa/tissue factor pathway. Coronary Artery Dis 9:83-87, 1998.
37. Levi M, van der Poll T, ten Cate H, van Deventer SJ: The cytokine-mediated imbalance between coagulant and anticoagulant mechanisms in sepsis and endotoxemia. Eur J Clin Invest 27:3-9, 1997.